359 research outputs found
Recommended from our members
Ethanol Production from Rice-Straw Hydrolysate Using Zymomonas Mobilis in a Continuous Fluidized-Bed Reactor (FBR)
Rice-straw hydrolysate obtained by the Arkenol's concentrated acid hydrolysis process was fermented to ethanol using a recombinant Zymomonas mobilis strain capable of utilizing both glucose and xylose in a continuous fluidized-bed reactor (FBR). The parameters studied included biocatalyst stability with and without antibiotic, feed composition, and retention time. Xylose utilization in the presence of tetracycline remained stable for at least 17 days. This was a significant improvement over the old strain, Z. mobilis CP4 (pZB5), which started to lose xylose utilization capability after seven days. In the absence of tetracycline, the xylose utilization rate started to decrease almost immediately. With tetracycline in the feed for the first six days, stability of xylose utilization was maintained for four days after the antibiotic was removed from the feed. The xylose utilization rate started to decrease on day 11. In the presence of tetracycline using the Arkenol's hydrolysate diluted to 48 g/L glucose and 13 g/L xylose at a retention time of 4.5 h, 95% xylose conversion and complete glucose conversion occurred. The ethanol concentration was 29 g/L, which gave a yield of 0.48 g/g sugar consumed or 94% of the theoretical yield. Using the Arkenol's hydrolysate diluted to 83 g/L glucose and 28 g/L xylose, 92% xylose conversion and complete glucose conversion were obtained. The ethanol concentration was 48 g/L, which gave a yield of 0.45 g/ g sugar consumed or 88% of the theoretical yield. Maximum productivity of 25.5 g/L-h was obtained at a retention time of 1.9 h. In this case, 84% xylose conversion was obtained
Sparing of the Dystrophin-Deficient Cranial Sartorius Muscle Is Associated with Classical and Novel Hypertrophy Pathways in GRMD Dogs
Both Duchenne and golden retriever muscular dystrophy (GRMD) are caused by dystrophin deficiency. The Duchenne muscular dystrophy sartorius muscle and orthologous GRMD cranial sartorius (CS) are relatively spared/hypertrophied. We completed hierarchical clustering studies to define molecular mechanisms contributing to this differential involvement and their role in the GRMD phenotype. GRMD dogs with larger CS muscles had more severe deficits, suggesting that selective hypertrophy could be detrimental. Serial biopsies from the hypertrophied CS and other atrophied muscles were studied in a subset of these dogs. Myostatin showed an age-dependent decrease and an inverse correlation with the degree of GRMD CS hypertrophy. Regulators of myostatin at the protein (AKT1) and miRNA (miR-539 and miR-208b targeting myostatin mRNA) levels were altered in GRMD CS, consistent with down-regulation of myostatin signaling, CS hypertrophy, and functional rescue of this muscle. mRNA and proteomic profiling was used to identify additional candidate genes associated with CS hypertrophy. The top-ranked network included α-dystroglycan and like-acetylglucosaminyltransferase. Proteomics demonstrated increases in myotrophin and spectrin that could promote hypertrophy and cytoskeletal stability, respectively. Our results suggest that multiple pathways, including decreased myostatin and up-regulated miRNAs, α-dystroglycan/like-acetylglucosaminyltransferase, spectrin, and myotrophin, contribute to hypertrophy and functional sparing of the CS. These data also underscore the muscle-specific responses to dystrophin deficiency and the potential deleterious effects of differential muscle involvement
Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis.
Psoralen plus UVA (PUVA) is used as a very effective treatment modality for various diseases, including psoriasis and cutaneous T-cell lymphoma. PUVA-induced immune suppression and/or apoptosis are thought to be responsible for the therapeutic action. However, the molecular mechanisms by which PUVA acts are not well understood. We have previously identified platelet-activating factor (PAF), a potent phospholipid mediator, as a crucial substance triggering ultraviolet B radiation-induced immune suppression. In this study, we used PAF receptor knockout mice, a selective PAF receptor antagonist, a COX-2 inhibitor (presumably blocking downstream effects of PAF), and PAF-like molecules to test the role of PAF receptor binding in PUVA treatment. We found that activation of the PAF pathway is crucial for PUVA-induced immune suppression (as measured by suppression of delayed type hypersensitivity to Candida albicans) and that it plays a role in skin inflammation and apoptosis. Downstream of PAF, interleukin-10 was involved in PUVA-induced immune suppression but not inflammation. Better understanding of PUVA\u27s mechanisms may offer the opportunity to dissect the therapeutic from the detrimental (ie, carcinogenic) effects and/or to develop new drugs (eg, using the PAF pathway) that act like PUVA but have fewer side effects
Osteopontin is linked with AKT, FoxO1, and myostatin in skeletal muscle cells
Introduction: Osteopontin (OPN) polymorphisms are associated with muscle size and modify disease progression in Duchenne muscular dystrophy (DMD). We hypothesized that OPN may share a molecular network with myostatin (MSTN).
Methods: Studies were conducted in the golden retriever (GRMD) and mdx mouse models of DMD. Follow-up in-vitro studies were employed in myogenic cells and the mdx mouse treated with recombinant mouse (rm) or human (Hu) OPN protein.
Results: OPN was increased and MSTN was decreased and levels correlated inversely in GRMD hypertrophied muscle. RM-OPN treatment led to induced AKT1 and FoxO1 phosphorylation, microRNA-486 modulation, and decreased MSTN. An AKT1 inhibitor blocked these effects, whereas an RGD-mutant OPN protein and an RGDS blocking peptide showed similar effects to the AKT inhibitor. RMOPN induced myotube hypertrophy and minimal Feret diameter in mdx muscle. Discussion: OPN may interact with AKT1/MSTN/FoxO1 to modify normal and dystrophic muscle
Changes in Muscle Metabolism are Associated with Phenotypic Variability in Golden Retriever Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is an X-chromosome-linked disorder and the most common monogenic disease in people. Affected boys are diagnosed at a young age, become non-ambulatory by their early teens, and succumb to cardiorespiratory failure by their thirties. Despite being a monogenic condition resulting from mutations in the DMD gene, affected boys have noteworthy phenotypic variability. Efforts have identified genetic modifiers that could modify disease progression and be pharmacologic targets. Dogs affected with golden retriever muscular dystrophy (GRMD) have absent dystrophin and demonstrate phenotypic variability at the functional, histopathological, and molecular level. Our laboratory is particularly interested in muscle metabolism changes in dystrophin-deficient muscle. We identified several metabolic alterations, including myofiber type switching from fast (type II) to slow (type I), reduced glycolytic enzyme expression, reduced and morphologically abnormal mitochondria, and differential AMP-kinase phosphorylation (activation) between hypertrophied and wasted muscle. We hypothesize that muscle metabolism changes are, in part, responsible for phenotypic variability in GRMD. Pharmacological therapies aimed at modulating muscle metabolism can be tested in GRMD dogs for efficacy
Online Monitoring of the Osiris Reactor with the Nucifer Neutrino Detector
Originally designed as a new nuclear reactor monitoring device, the Nucifer
detector has successfully detected its first neutrinos. We provide the second
shortest baseline measurement of the reactor neutrino flux. The detection of
electron antineutrinos emitted in the decay chains of the fission products,
combined with reactor core simulations, provides an new tool to assess both the
thermal power and the fissile content of the whole nuclear core and could be
used by the Inter- national Agency for Atomic Energy (IAEA) to enhance the
Safeguards of civil nuclear reactors. Deployed at only 7.2m away from the
compact Osiris research reactor core (70MW) operating at the Saclay research
centre of the French Alternative Energies and Atomic Energy Commission (CEA),
the experiment also exhibits a well-suited configuration to search for a new
short baseline oscillation. We report the first results of the Nucifer
experiment, describing the performances of the 0.85m3 detector remotely
operating at a shallow depth equivalent to 12m of water and under intense
background radiation conditions. Based on 145 (106) days of data with reactor
ON (OFF), leading to the detection of an estimated 40760 electron
antineutrinos, the mean number of detected antineutrinos is 281 +- 7(stat) +-
18(syst) electron antineutrinos/day, in agreement with the prediction 277(23)
electron antineutrinos/day. Due the the large background no conclusive results
on the existence of light sterile neutrinos could be derived, however. As a
first societal application we quantify how antineutrinos could be used for the
Plutonium Management and Disposition Agreement.Comment: 22 pages, 16 figures - Version
Conversion of deoxynivalenol to 3-acetyldeoxynivalenol in barley-derived fuel ethanol co-products with yeast expressing trichothecene 3-O-acetyltransferases
<p>Abstract</p> <p>Background</p> <p>The trichothecene mycotoxin deoxynivalenol (DON) may be concentrated in distillers dried grains with solubles (DDGS; a co-product of fuel ethanol fermentation) when grain containing DON is used to produce fuel ethanol. Even low levels of DON (†5 ppm) in DDGS sold as feed pose a significant threat to the health of monogastric animals. New and improved strategies to reduce DON in DDGS need to be developed and implemented to address this problem. Enzymes known as trichothecene 3-<it>O-</it>acetyltransferases convert DON to 3-acetyldeoxynivalenol (3ADON), and may reduce its toxicity in plants and animals.</p> <p>Results</p> <p>Two <it>Fusarium </it>trichothecene 3-<it>O-</it>acetyltransferases (FgTRI101 and FfTRI201) were cloned and expressed in yeast (<it>Saccharomyces cerevisiae</it>) during a series of small-scale ethanol fermentations using barley (<it>Hordeum vulgare</it>). DON was concentrated 1.6 to 8.2 times in DDGS compared with the starting ground grain. During the fermentation process, FgTRI101 converted 9.2% to 55.3% of the DON to 3ADON, resulting in DDGS with reductions in DON and increases in 3ADON in the Virginia winter barley cultivars Eve, Thoroughbred and Price, and the experimental line VA06H-25. Analysis of barley mashes prepared from the barley line VA04B-125 showed that yeast expressing FfTRI201 were more effective at acetylating DON than those expressing FgTRI101; DON conversion for FfTRI201 ranged from 26.1% to 28.3%, whereas DON conversion for FgTRI101 ranged from 18.3% to 21.8% in VA04B-125 mashes. Ethanol yields were highest with the industrial yeast strain Ethanol Red<sup>Ÿ</sup>, which also consumed galactose when present in the mash.</p> <p>Conclusions</p> <p>This study demonstrates the potential of using yeast expressing a trichothecene 3-<it>O</it>-acetyltransferase to modify DON during commercial fuel ethanol fermentation.</p
- âŠ